Understand the source comparison
How to Get Rid of Love Handles with Peptides: Mechanism Comparison
CJC-1295/Ipamorelin GHRH analog + GHRP. Amplifies endogenous GH pulse amplitude and duration 200–300 mcg each, subcutaneous, before sleep 2–4× baseline GH within 60 min Observational studies show 8–12% subcutaneous fat reduction over 12 weeks when combined wit
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- CJC-1295/Ipamorelin
- GHRH analog + GHRP. Amplifies endogenous GH pulse amplitude and duration
- 200–300 mcg each, subcutaneous, before sleep
- 2–4× baseline GH within 60 min
- Observational studies show 8–12% subcutaneous fat reduction over 12 weeks when combined with deficit
- Most researched stack for GH-mediated lipolysis. Effective when diet is structured
- Tesofensine
- Triple monoamine reuptake inhibitor. Raises norepinephrine, dopamine, serotonin; increases BMR 6–10%
- 0.25–0.5 mg oral, once daily AM
- Does not directly affect GH
- Phase 3 RCT: 12.8% body weight loss vs 2.0% placebo at 24 weeks
- Strongest clinical evidence for fat loss, but appetite suppression can hinder protein intake
- MK-677 (Ibutamoren)
- Ghrelin mimetic. Stimulates GH release for 24 hours
- 10–25 mg oral, once daily
- Sustained 50–80% GH elevation
- Mixed results. Some trials show modest fat loss, others show no change
- Better for lean mass retention than aggressive fat loss due to appetite increase
- AOD-9604
- Modified GH fragment (176–191). Claims to stimulate lipolysis without affecting IGF-1
- 250–500 mcg subcutaneous, AM fasted
- Does not raise systemic GH or IGF-1
- Limited human data. Mostly rodent studies showing localized fat reduction
- Mechanism plausible but clinical evidence insufficient to recommend